

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

	T		I	
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/631,871	07/31/2003	Sharon Mi Lyn Tan	03-044	1798
27774 7590 12/11/2008 MAYER & WILLIAMS PC 251 NORTH AVENUE WEST			EXAMINER	
			AZPURU, CARLOS A	
2ND FLOOR WESTFIELD,	NJ 07090		ART UNIT	PAPER NUMBER
,			1615	
			MAIL DATE	DELIVERY MODE
			12/11/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/631,871 TAN, SHARON MILYN Office Action Summary Examiner Art Unit Carlos A. Azpuru 1615 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 12 May 2008. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-22 is/are pending in the application. 4a) Of the above claim(s) _____ is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) 1-22 is/are rejected. 7) Claim(s) _____ is/are objected to. 8) Claim(s) _____ are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

Attachment(s)

1) Notice of References Cited (PTO-892)

1) Notice of Draftsperson's Patient Drawing Review (PTO-948)

3) Information: Disclosuse Statement(s) (PTO/Stice)

Paper No(s)/Mail Date

6) Other:

* See the attached detailed Office action for a list of the certified copies not received.

DETAILED ACTION

Applicant's request for reconsideration of the finality of the rejection of the last Office action is persuasive and, therefore, the finality of that action is withdrawn.

The following rejection is amended to include claims 6 and 22:

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Umemura et al (4,902,503) in view of Trogolo et al (US2003/0118664), both in view of McGlothlin et al (6,329,444).

The inclusion of antimicrobials such as silver in both natural and synthetic rubbers is disclosed by Unemura et al (see Abstract; claims). Heat curing (analogous to vulcanizing) is described at col. 5, lines 61-64. Unemura et al does not teach the encapsulation of the incorporated antimicrobials.

Art Unit: 1615

Trogolo teaches the microencapsulation of antimicrobial agents using hydrophilic polymers (see Abstract). The polymers used for encapsulation are listed from [0050] – [0065]. The antimicrobial and encapsulating polymer are blended together at [0066] to create a dispersed bioactive within the microcapsule. The inclusion of zeolite containing silver ions is disclosed at [0040]. Microcapsule diameter is disclosed at [0057] and clearly overlaps. Trogolo et al lacks a specific teaching of adding the antimicrobial microparticles to a rubber, but has a generic teaching of using them in polymers generically [0068]. Those of ordinary skill would have found it well within their skill to microencapsulate the antimicrobial found in Unemura et al in view of the teachings of Trogolo et al. which discloses the use of antimicrobial microparticles in various polymers.

Neither patent discloses that medical devices can be made from natural and synthetic rubbers, and additionally, the these rubbers can be dip molded. McGlothlin et al disclose both (see Abstract; col. 7, lines 45-49). Therefore, it would have been within the skill of the ordinary practitioner to microencapsulate antimicrobials in a latex as taught by Unemura et al in view of Trogollo et al, and further to form the instantly claimed medical devices through dip molding as taught by McGlothlin et al with a reasonable expectation of similar antimicrobial results. The instantly claimed latex with incorporated antimicrobial microparticles and method of making said latex would have therefore been obvious to one of ordinary skill at the time of invention given the teachings of Unemura et al in view of Trogolo et al, both in view of McGlothlin et al.

Application/Control Number: 10/631,871

Art Unit: 1615

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carlos A. Azpuru whose telephone number is (571) 272-0588. The examiner can normally be reached on Tu-Fri, 6:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on (571) 272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Carlos A. Azpuru/ Primary Examiner, Art Unit 1615 Application/Control Number: 10/631,871 Page 5

Art Unit: 1615